Spanish National Cancer Research Centre

What Spanish National Cancer Research Centre does

The Spanish National Cancer Research Centre (CNIO / Centro Nacional de Investigaciones Oncológicas), legally the Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III, is a public research foundation founded in 1998 and headquartered in Madrid. It operates under the Spanish Ministry of Science, Innovation and Universities and employs roughly 500 scientists plus support staff (501–1000 total headcount range). CNIO is not a commercial product company; it generates knowledge, creates and transfers technology, and delivers oncology research training, positioning itself as the principal cancer research centre in Spain and one of the top-ten monographic cancer research centres globally.

Its scientific work spans multidisciplinary programmes including Cancer Biology, Molecular Oncology, Clinical Research, Structural Biology, Computational Cancer Genomics, Population and Precision Genomics, and Experimental Therapies. Notable technical capabilities include CAR-T and STAb-T cell immunotherapy (including LIVE-STAb in vivo T-cell generation co-developed with Germany's Paul-Ehrlich-Institut), the first-in-class MeCo Score predictive biomarker for antifibrotic therapy selection in HER2-negative breast cancer, protein nanoparticle design ("Protein Lego") integrated with cryo-electron microscopy, a triple-drug pancreatic cancer therapy that eradicated tumours in mouse models, and MIF-CD74 signalling research underpinning a brain-metastasis collaboration with MediciNova. CNIO's bioinformatics unit analyses genomic data from millions of cells across thirty cancer types and participates in the European 1+Million Genomes initiative.

CNIO's economics are those of a publicly funded non-profit rather than a revenue-generating enterprise. Its funding mechanics combine core government budget allocations, competitive research grants (e.g., a €10M ERC grant to Guadalupe Sabio, a €320,000 Instituto de Salud Carlos III grant for the MeCo Score, and AECC grants across ~a dozen projects), philanthropic donations via the CNIO Friends programme (ranging from €10 to over €100,000), and crowdfunding (nearly €800,000 raised in five days for Barbacid's pancreatic trial). Value is captured commercially through technology transfer and spin-offs such as MeCo Diagnostics and STAB Therapeutics, plus embedded clinical research units in partner hospitals (Hospital 12 de Octubre, Hospital La Paz / IdiPAZ). Its "customers" and beneficiaries are cancer patients and the public, the scientific and clinical research community, philanthropic donors, and international research institutions.

Name

Spanish National Cancer Research Centre

Legal name

Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III

Website

https://cnio.es

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

501–1,000 employees

Short description

CNIO is Spain's largest public cancer research centre, founded 1998 in Madrid with ~500 scientists. It conducts multidisciplinary oncology research—immunotherapy, genomics, biomarkers—transferring technology via spin-offs and clinical units serving patients, clinicians, and research institutions.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Scientific Research and Development Services (5417), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

akta.pro secondary industries

Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Neuro-oncology (HLAKAIAL), Neuro-Oncology (HLAKAFAH)

Keywords

• Cancer research programs
• Clinical oncology research
• Immunotherapy development
• Genomic medicine research
• Biomarker discovery

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Institutional Government Funding: CNIO is a public institution dependent on the Ministry of Science, Innovation and Universities (Ministerio de Ciencia, Innovación y Universidades). Core operational funding comes from government budget allocations.
2. Research Grants and Project Funding: Competitive grant funding from national and international bodies such as Instituto de Salud Carlos III (€320,000 grant for MeCo Score), European Research Council (€10 million ERC grant to Guadalupe Sabio), Deutsche José Carreras Leukämie Stiftung (LIVE-STAb project), and AECC (Spanish Association Against Cancer).
3. Philanthropic Donations (CNIO Friends): The CNIO Friends programme receives donations (ranging from €10 to over €100,000) from individuals, patient organisations, and companies. All funds are allocated entirely to recruiting young researchers and acquiring essential equipment. Major donors include Fundación Domingo Martínez, Fundación Humanismo y Ciencia, Fundación Juegaterapia, and La Roche-Posay (L'Oréal Dermatological Beauty group).
4. Clinical Services and Diagnostics: CNIO provides specialized diagnostic and research services. The IGESTLAB/Gestlab web platform manages petetioning, results, reports, and testing for registered users including healthcare professionals.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

CNIO is a public research institution that conducts multidisciplinary cancer research, operates hospital-embedded clinical research units running oncology trials, provides bioinformatics and genomic data services, develops novel immunotherapies and biomarkers (e.g., STAb-T cells, MeCo Score), and delivers postgraduate education and training in oncology research. Outputs are disseminated through scientific publications, technology transfer via spin-offs and licensing, and outreach programmes to the general public.

Product overview

The Spanish National Cancer Research Centre (CNIO) is a public research institution and not a commercial product company. Its offerings consist of cancer research programs (covering molecular oncology, tumour biology, structural biology, and clinical research), bioinformatics and genomic analysis services, clinical trials across multiple tumour types, education and training programmes including a Master's in Bioinformatics, the CNIO Friends philanthropic funding initiative, and public outreach activities. These services collectively aim to improve cancer prevention, diagnosis, and treatment through scientific research, technology transfer, and knowledge dissemination.

Differentiator

Problem solved

Functional benefit

Brands

• CNIO Friends: A philanthropy program that supports excellent cancer research through donations, helping attract research talent and acquire essential equipment
• CNIO-CaixaResearch Frontiers Meetings

Products and services

• CNIO Research Programs Comprehensive cancer research programmes covering molecular oncology, tumour biology, structural biology, clinical research and population genomics aimed at improving the prevention, diagnosis, and treatment of cancer. Audience: cancer patients (ultimate beneficiaries), the scientific research community, and healthcare professionals.
• CNIO Clinical Research Units Hospital-embedded clinical research units running trials in breast cancer, cancer immunotherapy, paediatric oncohaematology, lung cancer, and haematological tumours, translating CNIO's scientific discoveries into patient treatments. Audience: hospital partners, clinicians and patients enrolled in trials.
• CNIO Bioinformatics Services Bioinformatics and genomic data services analysing data from millions of cells across thirty cancer types, developing tools for biomarker identification, molecular tumour characterisation and precision medicine decision support. Audience: CNIO's own researchers and partner institutions.
• Master's in Bioinformatics and Data Science in Personalised Precision Medicine and Health Postgraduate academic programme providing training in bioinformatics and data science applied to personalised precision medicine and health, co-delivered with ISCIII, BSC-CNS and SEBiot. Audience: postgraduate students and early-career researchers.
• CNIO Friends Programme Philanthropic initiative funding cancer research through donations from individuals, patient organisations and companies; 100% of donations allocated to recruiting young researchers and acquiring essential equipment. Audience: individual donors, patient organisations, corporate donors and foundations.

Quantifiable outcome

• 62% reduction in risk of recurrence for high MeCo Score early-stage breast cancer patients receiving neoadjuvant antifibrotic therapy plus chemotherapy vs chemotherapy alone after 9.7 years median follow-up
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core, minor and major.

• MediciNovacoreStrategic or Co-development Partner · 27 April 2026CNIO and MediciNova plan to collaborate on future clinical research aimed at patients with solid tumors having brain metastases. CNIO researchers identified MIF-mediated reprogramming of CD74-positive microglia and macrophages as a central vulnerability in brain metastasis, and MediciNova's drug ibudilast (MN-166) can block this signaling pathway to suppress brain metastasis growth.
• MeCo DiagnosticscoreStrategic or Co-development Partner · 26 February 2026MeCo Diagnostics collaborates with Dr. Miguel Quintela-Fandino at CNIO to advance the MeCo Score for HER2-negative breast cancer. The MeCo Score is a first-in-class predictive biomarker guiding antifibrotic therapy selection in oncology, with clinical validation showing a 62% reduction in recurrence risk for high MeCo Score patients.
• Fundación The Pink ForceminorStrategic or Co-development Partner · 26 September 2025CNIO volunteers collaborated with Fundación The Pink Force to build and deliver two R2-KT toy robots to children with cancer at Hospital Universitario La Paz's paediatric oncology ward. The robots were assembled at CNIO and delivered through the Hospital's paediatric oncology classroom.
• Paul-Ehrlich-Institut (Germany)majorStrategic or Co-development PartnerThe Paul-Ehrlich-Institut, Germany's federal regulatory authority for biomedical products, co-leads the LIVE-STAb project with Luis Álvarez-Vallina's group at CNIO to develop in vivo generation of BCMA-targeted STAb-T cells for multiple myeloma treatment, directly within the patient.
• STAB TherapeuticsmajorStrategic or Co-development PartnerSTAB Therapeutics, a spin-off based on research by Luis Álvarez-Vallina (head of the CNIO-HMarBCN Clinical Research Unit in Cancer Immunotherapy), received AECC funding to develop new cellular immunotherapy as a treatment option for brain tumors, moving toward a Phase 1 clinical trial.
• European 1+Million Genomes Initiative (1+MG)coreStrategic or Co-development PartnerCNIO is one of the 'hubs' for Spain's participation in the European 1+Million Genomes initiative, which aims to extend the benefits of genomics to national healthcare systems across Europe.

Scale indicators8 records

Direct peers

• Vall d'Hebron Institute of Oncology (VHIO): Spanish public cancer research institute embedded in the Vall d'Hebron University Hospital in Barcelona. Closest domestic peer to CNIO with the same public-mandate, hospital-embedded translational model and overlapping tumour-type programmes.
• Institut Curie: French public cancer research centre combining research, hospital, and technology transfer. Operates a similar model to CNIO: multidisciplinary cancer research, embedded clinical activity, and spin-off creation — and serves as a natural cross-border comparator in European public-sector oncology.
• German Cancer Research Center (DKFZ): Germany's national public cancer research centre and the largest in Europe. DKFZ is the closest direct peer to CNIO: same public-mandate model, multidisciplinary cancer programmes (biology, genomics, translational, clinical), hospital-embedded units, technology transfer to spin-offs, and roughly comparable international standing.
• European Institute of Oncology (IEO): Italian comprehensive cancer centre combining research, treatment, and training. Same integrated research-plus-clinical model as CNIO and a natural Southern-European comparator for translational cancer research and clinical-trial capacity.
• Institute of Cancer Research (ICR): UK research university and charity dedicated to cancer, combining laboratory science with clinical trials at The Royal Marsden. Highly comparable to CNIO in combining cancer biology, translational research, drug discovery, and hospital-embedded trials.

Broad incumbents

• Francis Crick Institute: Large UK biomedical research institute with significant cancer research alongside other diseases. Comparable to CNIO in scale (~1,500 scientists), public-mandate funding model, and multidisciplinary discovery science, though not exclusively focused on oncology.
• Karolinska Institutet: Swedish medical university with large-scale cancer research and an embedded university hospital. Comparable to CNIO in combining cancer research, clinical translation, and doctoral training, and serves as a Nordic reference point for public-sector oncology research.
• Memorial Sloan Kettering Cancer Center: US cancer centre combining laboratory research with high-volume clinical care. Comparable to CNIO in integrating research and clinical programmes, especially in immunotherapy, and a recognised global benchmark for translational oncology even though its scale and budget are far larger.
• National Cancer Institute (NCI / NIH): The US federal cancer research agency within NIH. Same public-mandate, multi-programme cancer research structure as CNIO but orders of magnitude larger in budget and headcount; defines the global benchmark CNIO is benchmarked against in the 'top-10 monographic centres' framing.

Emerging players

• Broad Institute of MIT and Harvard: US research institute focused on genomics, cancer, and computational biology. Comparable to CNIO in the genomics/bioinformatics pillar (which underpins CNIO's Computational Cancer Genomics and the 30-cancer-type genomic dataset) but with a much larger technology and platform mandate.

Market position

Strengths5 records

Weaknesses5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/cnio_cancer
• YouTubeyoutube.com/canalcnio
• Facebookfacebook.com/hazteamigodelcnio
• LinkedInlinkedin.com/company/cnio
• Instagraminstagram.com/CNIOStopCancer

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spanish National Cancer Research Centre